Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Administration of first dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
4 |
Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
4 |
Diphtheria/tetanus/pertussis/inactivated poliomyelitis vaccine 0.5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
kighostevaccine |
Inferred relationship |
Some |
|
Administration of second dose of pertussis vaccine |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
1 |
Administration of booster dose of pertussis vaccine |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
1 |
Administration of third dose of pertussis vaccine |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
1 |
Administration of first dose of pertussis vaccine |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
1 |
kighostevaccination, ikke nærmere specificeret |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
1 |
Administration of pertussis vaccine |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
1 |
Diphtheria + acellular pertussis adsorbed + inactivated polio + tetanus toxoids vaccine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
kighostevaccine |
Inferred relationship |
Some |
1 |
Acellular pertussis vaccine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
kighostevaccine |
Inferred relationship |
Some |
1 |
Allergy to pertussis vaccine |
Causative agent |
False |
kighostevaccine |
Inferred relationship |
Some |
1 |
Allergy to diphtheria and pertussis and tetanus vaccine |
Causative agent |
False |
kighostevaccine |
Inferred relationship |
Some |
3 |
Administration of tetanus, diphtheria, and acellular pertussis vaccine |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
3 |
Administration of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (procedure) |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
1 |
Administration of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Hepatitis B virus and inactivated whole Human poliovirus antigens (procedure) |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
3 |
Administration of vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and inactivated whole Human poliovirus antigens (procedure) |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
3 |
Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Hepatitis B virus antigens (procedure) |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
4 |
Administration of third dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Hepatitis B virus antigens (procedure) |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
5 |
Administration of second dose of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b and Hepatitis B virus antigens (procedure) |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
1 |
Administration of first dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
4 |
Vaccination for diphtheria, pertussis, tetanus, poliomyelitis, Hepatitis B virus and Haemophilus influenzae type b |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
2 |
Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
kighostevaccine |
Inferred relationship |
Some |
3 |
Administration of vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type b antigens (procedure) |
Direct substance |
False |
kighostevaccine |
Inferred relationship |
Some |
1 |
difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighoste-vaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigen 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt injektionssprøjte |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
kighostevaccine |
Inferred relationship |
Some |
4 |
difteritoxoid 30 IE/tetanustoxoid 40 IE/acellulær kighostetoxoid 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
kighostevaccine |
Inferred relationship |
Some |
2 |
rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + acellulær kighostevaccine 25 µg injektionsvæske, opløsning i fyldt injektionssprøjte a 0,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
kighostevaccine |
Inferred relationship |
Some |
3 |